PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Manzardo, Christian
TI  - Efavirenz-Based Therapy Effective in Highly Suppressed HIV-1–Infected Patients
DP  - 2015 Jul 23
TA  - MD Conference Express
PG  - 20--21
VI  - 15
IP  - 48
4099  - http://mdc.sagepub.com/content/15/48/20.short
4100  - http://mdc.sagepub.com/content/15/48/20.full
AB  - In the ADVANZ-3 trial, among patients with advanced HIV-1, 96 weeks of daily combination treatment with efavirenz plus tenofovir/emtricitabine is as effective in increasing CD4+ T-cell levels as daily combination treatment using atazanavir/ritonavir plus tenofovir/emtricitabine or lopinavir/ritonavir plus tenofovir/emtricitabine. Similar improvements are also seen for inflammation, coagulation, and bacterial translocation markers.